Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) was up 3% during mid-day trading on Monday . The company traded as high as C$6.70 and last traded at C$6.60. Approximately 794,307 shares changed hands during mid-day trading, an increase of 10,619% from the average daily volume of 7,410 shares. The stock had previously closed at C$6.41.
Eupraxia Pharmaceuticals Trading Up 3.0%
The company’s fifty day moving average price is C$6.89 and its 200 day moving average price is C$7.39.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
